Cambridge Investment Research Advisors
IMDX

Cambridge Investment Research Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,825
Closed -$33K – 3134
2022
Q2 		$33K Sell
1,825
-30
-2% -$682 ﹤0.01% 2971
2022
Q1 		$55K Sell
1,855
-175
-9% -$5.59K ﹤0.01% 3068
2021
Q4 		$88K Hold
2,030
– – ﹤0.01% 3048
2021
Q3 		$145K Sell
2,030
-300
-13% -$27.6K ﹤0.01% 2887
2021
Q2 		$267K Sell
2,330
-50
-2% -$4.88K ﹤0.01% 2559
2021
Q1 		$247K Buy
+2,380
New +$226K ﹤0.01% 2437

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Cambridge Investment Research Advisors's IMDX Position: Q3 2022 in Review

Cambridge Investment Research Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q3 2022, closing a stake of 1,825 shares — an estimated $33K sold.

Cambridge Investment Research Advisors first reported a position in IMDX in Q1 2021 and held it in 6 quarters. The position peaked at $267K in Q2 2021. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

  • Cambridge Investment Research Advisors reported no remaining Insight Molecular Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,825 Insight Molecular Diagnostics shares in Q3 2022, an estimated $33K.
  • Cambridge Investment Research Advisors first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 6 quarters.
  • Cambridge Investment Research Advisors's Insight Molecular Diagnostics position peaked at $267K in Q2 2021.
  • 65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.